CYCC
Income statement / Annual
Last year (2023), Cyclacel Pharmaceuticals, Inc.'s total revenue was $420,000.00,
and the percentage change from the previous year is not available.
In 2023, Cyclacel Pharmaceuticals, Inc.'s net income was -$22.56 M.
See Cyclacel Pharmaceuticals, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$420,000.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$150,000.00
|
$0.00
|
$843,000.00
|
$1.94 M
|
$1.73 M
|
| Cost of Revenue |
$31,000.00 |
$32,000.00 |
$43,000.00 |
$20,000.00 |
$20,000.00 |
$4.33 M |
$32,000.00 |
$9.48 M |
$12.38 M |
$18.28 M |
| Gross Profit |
$389,000.00 |
-$32,000.00 |
-$43,000.00 |
-$20,000.00 |
-$20,000.00 |
-$4.18 M |
-$32,000.00 |
-$8.63 M |
-$10.44 M |
-$16.54 M |
| Gross Profit Ratio |
0.93 |
0 |
0 |
0 |
0 |
-27.85 |
0 |
-10.24 |
-5.37 |
-9.54 |
| Research and Development
Expenses |
$19.16 M
|
$20.27 M
|
$15.48 M
|
$4.76 M
|
$4.66 M
|
$4.33 M
|
$4.24 M
|
$9.48 M
|
$12.38 M
|
$18.28 M
|
| General & Administrative
Expenses |
$6.72 M
|
$7.38 M
|
$7.46 M
|
$5.88 M
|
$5.02 M
|
$5.37 M
|
$5.25 M
|
$5.52 M
|
$5.73 M
|
$5.89 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$20,000.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$6.72 M
|
$7.38 M
|
$7.46 M
|
$5.88 M
|
$5.02 M
|
$5.37 M
|
$5.25 M
|
$5.52 M
|
$5.75 M
|
$5.89 M
|
| Other Expenses |
$0.00 |
$1.30 M |
$144,000.00 |
$891,000.00 |
$231,000.00 |
$682,000.00 |
$949,000.00 |
$0.00 |
$12,132.00 |
$0.00 |
| Operating Expenses |
$25.87 M |
$27.66 M |
$22.94 M |
$10.64 M |
$9.68 M |
$9.70 M |
$9.49 M |
$14.99 M |
$18.13 M |
$24.17 M |
| Cost And Expenses |
$25.87 M |
$27.66 M |
$22.94 M |
$10.64 M |
$9.68 M |
$9.70 M |
$9.49 M |
$14.99 M |
$18.13 M |
$24.17 M |
| Interest Income |
$266,000.00 |
$210,000.00 |
$16,000.00 |
$42,000.00 |
$224,000.00 |
$331,000.00 |
$118,000.00 |
$37,000.00 |
$9,000.00 |
$6,000.00 |
| Interest Expense |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Depreciation &
Amortization |
$31,000.00
|
$32,000.00
|
$43,000.00
|
$20,000.00
|
$20,000.00
|
$29,000.00
|
$32,000.00
|
$133,000.00
|
$210,000.00
|
$174,000.00
|
| EBITDA |
-$25.42 M
|
-$27.62 M
|
-$22.69 M
|
-$10.62 M
|
-$9.66 M
|
-$9.52 M
|
-$9.46 M
|
-$14.02 M
|
-$15.96 M
|
-$22.26 M
|
| EBITDA Ratio |
-60.53 |
0 |
0 |
0 |
0 |
-63.05 |
0 |
-17.19 |
-8.17 |
-12.81 |
| Operating Income Ratio
|
-60.6
|
0
|
0
|
0
|
0
|
-63.65
|
0
|
-16.79
|
-8.32
|
-12.94
|
| Total Other
Income/Expenses Net |
-$98,000.00
|
$1.74 M
|
$204,000.00
|
$955,000.00
|
$556,000.00
|
$923,000.00
|
$1.03 M
|
$376,000.00
|
-$316,000.00
|
-$212,000.00
|
| Income Before Tax |
-$25.55 M |
-$25.92 M |
-$22.73 M |
-$9.68 M |
-$9.13 M |
-$8.63 M |
-$8.46 M |
-$13.77 M |
-$16.49 M |
-$22.65 M |
| Income Before Tax Ratio
|
-60.84
|
0
|
0
|
0
|
0
|
-57.5
|
0
|
-16.34
|
-8.48
|
-13.06
|
| Income Tax Expense |
-$3.00 M |
-$4.72 M |
-$3.85 M |
-$1.24 M |
-$1.30 M |
-$1.34 M |
-$993,000.00 |
-$1.98 M |
-$2.14 M |
-$3.24 M |
| Net Income |
-$22.56 M |
-$21.20 M |
-$18.89 M |
-$8.45 M |
-$7.83 M |
-$7.29 M |
-$7.47 M |
-$11.79 M |
-$14.34 M |
-$19.39 M |
| Net Income Ratio |
-53.7 |
0 |
0 |
0 |
0 |
-48.59 |
0 |
-13.99 |
-7.38 |
-11.18 |
| EPS |
-26.75 |
-32.23 |
-31.74 |
-34.86 |
-143.88 |
-12.05 |
-19.58 |
-68.85 |
-105.72 |
-211.93 |
| EPS Diluted |
-26.75 |
-32.23 |
-31.74 |
-34.86 |
-143.88 |
-12.05 |
-19.58 |
-68.85 |
-105.72 |
-211.93 |
| Weighted Average Shares
Out |
$850,815.00
|
$657,616.00
|
$595,078.00
|
$242,225.00
|
$54,405.00
|
$604,706.00
|
$381,557.00
|
$171,248.00
|
$135,654.00
|
$91,480.00
|
| Weighted Average Shares
Out Diluted |
$850,815.00
|
$657,616.00
|
$595,078.00
|
$242,225.00
|
$54,405.00
|
$604,706.00
|
$381,557.00
|
$171,248.00
|
$135,654.00
|
$91,480.00
|
| Link |
|
|
|
|
|
|
|
|
|
|
